Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

NCT01148810 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Trial was prematurely terminated due to enrollment challenges.

Conditions

Polymyositis
Dermatomyositis

Interventions

DRUG: BAF312
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals